Kenchappa, R. S., Radnai, L., Young, E. J., Zarco, N., Lin, L., Dovas, A., Meyer, C. T., Haddock, A., Hall, A., Toth, K., Canoll, P., Nagaiah, N. K. H., Rumbaugh, G., Cameron, M. D., Kamenecka, T. M., Griffin, P. R., Miller, C. A., & Rosenfeld, S. S. (2025). MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma. Cell. https://doi.org/10.1016/j.cell.2025.05.019

Lu, C., Kang, T., Zhang, J., Yang, K., Liu, Y., Song, K., Lin, Q., Dixit, D., Gimple, R. C., Zhang, Q., Shi, Z., Fan, X., Wu, Q., Li, D., Shan, D., Gao, J., Gu, D., You, H., Li, Y., … Wang, X. (2025). Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-58366-5

Bhatnagar, A., Marin, M. P., Lischalk, J. W., Koh, M. J., Agazzi, S., Suy, S., Harris, B. T., Sharma, S. T., Aulisi, E., Anaizi, A., Khattab, M. H., Jean, W. C., Collins, S. P., & Collins, B. T. (2025). Fractionated robotic radiosurgery for unfavorable nonfunctioning pituitary macroadenoma: 5-year outcomes from a single institution protocol. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1519445

Haile, H., Upadhyayula, P. S., Karlovich, E., Sisti, M. B., Gill, B. J. A., & Donovan, L. E. (2025). Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report. Acta Neuropathologica Communications, 13(1). https://doi.org/10.1186/s40478-024-01894-w

Mendez, J. S., Cohen, A. L., Eckenstein, M., Jensen, R. L., Burt, L. M., Salzman, K. L., Chamberlain, M., Hsu, H. H., Hutchinson, M., Iwamoto, F., Ligon, K. L., Mrugala, M. M., Pelayo, M., Plotkin, S. R., Puduvalli, V. K., Raizer, J., Reardon, D. A., Sterba, M., Walbert, T., … Colman, H. (2024). Phase 1b/2 Study of Orally Administered Pexidartinib in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdae202

Zarco, N., Dovas, A., de Araujo Farias, V., Nagaiah, N. K. H., Haddock, A., Sims, P. A., Hambardzumyan, D., Meyer, C. T., Canoll, P., Rosenfeld, S. S., & Kenchappa, R. S. (2024). Resistance to spindle inhibitors in glioblastoma depends on STAT3 and therapy induced senescence. IScience, 27(12), 111311. https://doi.org/10.1016/j.isci.2024.111311

Wang, H., Argenziano, M. G., Yoon, H., Boyett, D., Save, A., Petridis, P., Savage, W., Jackson, P., Hawkins-Daarud, A., Tran, N., Hu, L., Singleton, K. W., Paulson, L., Dalahmah, O. A., Bruce, J. N., Grinband, J., Swanson, K. R., Canoll, P., & Li, J. (2024). Biologically informed deep neural networks provide quantitative assessment of intratumoral heterogeneity in post treatment glioblastoma. Npj Digital Medicine, 7(1). https://doi.org/10.1038/s41746-024-01277-4

Zhang, C., Zhao, N., Khan, R., Hung, M., Zhang, C., Wang, S., Wang, T. J. C., & Lin, C. (2024). The prognostic significance of androgen receptor expression in gliomas. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-72284-4

Latzer, P., Zelba, H., Battke, F., Reinhardt, A., Shao, B., Bartsch, O., Rabsteyn, A., Harter, J., Schulze, M., Okech, T., Golf, A., Kyzirakos-Feger, C., Kayser, S., Pieper, N., Feldhahn, M., Wünsche, J., Seitz, C., Hadaschik, D., Garbe, C., … Biskup, S. (2024). A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51315-8

Mrugala, M. M., Shi, W., Iwomoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2024). Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022. Journal of Neuro-Oncology, 169(1), 25–38. https://doi.org/10.1007/s11060-024-04682-7

Nguyen, T. T. T., Greene, L. A., Mnatsakanyan, H., & Badr, C. E. (2024). Revolutionizing Brain Tumor Care: Emerging Technologies and Strategies. Biomedicines, 12(6), 1376. https://doi.org/10.3390/biomedicines12061376

Crawford, J. R., Lo, Y. Y., Pagadala, M. S., Chapman, O. S., Sridhar, S., Juarez, E. F., Tzaridis, T., Chau, L. Q., Wang, J., Eisemann, T., Masihi, M. B., Chambers, K. R., Dixit, D., Koubourli, D., Larson, J. D., Guidugli, L., Hammer, M., Wong, T., Abdullaev, Z., … Wechsler-Reya, R. J. (2024). TRLS-13. MULTI-OMICS AND FUNCTIONAL PRECISION MEDICINE FOR NEWLY DIAGNOSED AND RECURRENT PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.166

Minns, H. E., Padilla, O., Wei, H.-J., Webster-Carrion, A., Gallitto, M., Szalontay, L., Pavisic, J., Tan, Y., Deoli, N., Garty, G., Garvin, J. H., Canoll, P., Vanpouille-Box, C. I., Rabadan, R., Wu, C.-C., & Gartrell, R. D. (2024). RADT-09. IMMUNE RESPONSE IN DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING FLASH OR CONVENTIONAL RADIATION. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.769

Szalontay, L., CreveCoeur, T., Neira, J., Englander, Z., Spinazzi, E., Canoll, P., Garvin, J., Fino, J., Zamoryakhin, D., Maddocks, A., Feldstein, N., Bruce, J., Wu, C.-C., & Zacharoulis, S. (2024). SURG-07. A PHASE I STUDY EXAMINING THE FEASIBILITY OF INTERMITTENT CONVECTION-ENHANCED DELIVERY (CED) OF MTX110 FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.648

Larson, J. D., Finlay, D., Murad, R., Lo, Y. Y., Zhao, M., Manuvel, A. M. K., Kumar, S. A., Pass, I., Handley, C., Wechsler-Reya, R. J., Taylor, M. D., Vuori, K., Chavez, L., & Jackson, M. (2024). EPEN-26. DRUG SCREENING IN PATIENT-DERIVED MODELS OF POSTERIOR FOSSA A EPENDYMOMA REVEALS NOVEL PHARMACOLOGICAL VULNERABILITIES. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.228

Kline, C., Crawford, J. R., Reddy, A. T., Gerber, N., Stucklin, A. G., Kilburn, L., Packer, R., Margol, A., Crotty, E., Sayour, E., Franson, A., Phillips, J., Singh, S., Hamanishi, E., Lee, C., Bhatia, A., George, E., Rauschecker, A., Molinaro, A., … Mueller, S. (2024). TRLS-07. PNOC016: INTRATUMORAL PHARMACOKINETICS AND PHARMACODYNAMIC (PK/PD) RESULTS FROM A TARGET VALIDATION STUDY OF A NOVEL PAN-HDAC AND PI3K INHIBITOR, FIMEPINOSTAT, IN CHILDREN AND YOUNG ADULTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG), RECURRENT MEDULLOBLASTOMA (MB), AND RECURRENT HIGH-GRADE GLIOMA (HGG). Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.160

Gallitto, M., De Santos, G. L., Wei, H.-J., Zhang, X., Zhang, Z., & Wu, C.-C. (2024). DIPG-41. CONVECTION ENHANCED DELIVERY-MEDIATED RADIOSENSITIZATION FOR DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.094

Kenkre, R., Chapman, O., Luebeck, J., Bafna, V., Wechsler-Reya, R. J., Mesirov, J., & Chavez, L. (2024). STEM-07. CONSERVATION AND FAITHFUL REPRESENTATION OF CIRCULAR EXTRACHROMOSOMAL DNA IN ORTHOTOPIC PATIENT-DERIVED MEDULLOBLASTOMA XENOGRAFTS. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.778

Katsushima, K., Joshi, K., Yuan, M., Batish, M., Stapleton, S., Jallo, G., Seal, S., Taylor, M. D., Wechsler-Reya, R. J., Eberhart, C. G., & Perera, R. J. (2024). MDB-01. A POSITIVE FEEDBACK LOOP BETWEENLNC-HLX-2-7, HLX, AND MYC STRONGLY PROMOTES GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.450

Shatara, M., Paul, M. R., Long-Boyle, J. R., Meyer, A., Raber, S., Yeh-Nayre, L., Jalkanen, A., Kilburn, L. B., Packer, R. J., Elster, J. D., Reddy, A. T., Koschmann, C., Kraya, A., Resnick, A. C., Prados, M., Kline, C., Mueller, S., Wechsler-Reya, R. J., & Rubin, J. B. (2024). TRLS-04. EARLY INSIGHTS FROM PNOC027: PERSONALIZED TREATMENT APPROACHES BASED ON REAL-TIME DRUG SCREENING AND GENOMIC TESTING IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RECURRENT MEDULLOBLASTOMA. Neuro-Oncology, 26(Supplement_4), 0–0. https://doi.org/10.1093/neuonc/noae064.157

Watanabe, J., Clutter, M. R., Gullette, M. J., Sasaki, T., Uchida, E., Kaur, S., Mo, Y., Abe, K., Ishi, Y., Takata, N., Natsumeda, M., Gadd, S., Zhang, Z., Becher, O. J., & Hashizume, R. (2024). BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma. Journal of Clinical Investigation, 134(13). https://doi.org/10.1172/jci174794

Lin, A. L., Rudneva, V. A., Richards, A. L., Zhang, Y., Woo, H. J., Cohen, M., Tisnado, J., Majd, N., Wardlaw, S. L., Page-Wilson, G., Sengupta, S., Chow, F., Goichot, B., Ozer, B. H., Dietrich, J., Nachtigall, L., Desai, A., Alano, T., Ogilive, S., … Tabar, V. (2024). Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors. Acta Neuropathologica, 147(1). https://doi.org/10.1007/s00401-024-02736-8

Cheng, Y. L., Banu, M. A., Zhao, W., Rosenfeld, S. S., Canoll, P., & Sims, P. A. (2024). Multiplexed single-cell lineage tracing of mitotic kinesin inhibitor resistance in glioblastoma. Cell Reports, 43(5), 114139. https://doi.org/10.1016/j.celrep.2024.114139

Wang, L., Wang, H., D’Angelo, F., Curtin, L., Sereduk, C. P., Leon, G. D., Singleton, K. W., Urcuyo, J., Hawkins-Daarud, A., Jackson, P. R., Krishna, C., Zimmerman, R. S., Patra, D. P., Bendok, B. R., Smith, K. A., Nakaji, P., Donev, K., Baxter, L. C., Mrugała, M. M., … Li, J. (2024). Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm. PLOS ONE, 19(4), e0299267. https://doi.org/10.1371/journal.pone.0299267

Schneider, M., Potthoff, A., Karpel‐Massler, G., Schuss, P., Siegelin, M. D., Debatin, K., Duffau, H., Vatter, H., Herrlinger, U., & Westhoff, M. (2024). The Alcatraz‐Strategy: a roadmap to break the connectivity barrier in malignant brain tumours. Molecular Oncology. Portico. https://doi.org/10.1002/1878-0261.13642

Tzaridis, T., & Wechsler-Reya, R. J. (2024). Just a spoonful of metformin helps the medicine go down. Journal of Clinical Investigation, 134(6). https://doi.org/10.1172/jci179144

Hébert, J., De Santis, R. J., Daniyal, L., Mannan, S., Ng, E., Thain, E., Sanabria-Salas, M. C., Kim, R. H., Bril, V., & Reid, A. Y. (2024). Epilepsy in neurofibromatosis type 1: Prevalence, phenotype, and genotype in adults. Epilepsy Research, 202, 107336. https://doi.org/10.1016/j.eplepsyres.2024.107336

Gallitto, M., Pan, P. C., Chan, M. D., Milano, M. T., & Wang, T. J. C. (2024). The role of radiotherapy in immunotherapy strategies in the central nervous system. Neuro-Oncology, 26(Supplement_1), S66–S75. https://doi.org/10.1093/neuonc/noad184

Lee, I. Y., Hanft, S., Schulder, M., Judy, K. D., Wong, E. T., Elder, J. B., Evans, L. T., Zuccarello, M., Wu, J., Aulakh, S., Agarwal, V., Ramakrishna, R., Gill, B. J., Quiñones-Hinojosa, A., Brennan, C., Zacharia, B. E., Silva Correia, C. E., Diwanji, M., Pennock, G. K., … Boockvar, J. A. (2024). Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients. Future Oncology, 20(10), 579–591. https://doi.org/10.2217/fon-2023-0702

Cao, Q., Hajosch, A., Kast, R. E., Loehmann, C., Hlavac, M., Fischer-Posovszky, P., Strobel, H., Westhoff, M.-A., Siegelin, M. D., Wirtz, C. R., Halatsch, M.-E., & Karpel-Massler, G. (2024). Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British Journal of Cancer, 130(8), 1365–1376. https://doi.org/10.1038/s41416-024-02608-8

Galbraith, K., Vasudevaraja, V., Serrano, J., Shen, G., Tran, I., Abdallat, N., Wen, M., Patel, S., Movahed-Ezazi, M., Faustin, A., Spino-Keeton, M., Roberts, L. G., Maloku, E., Drexler, S. A., Liechty, B. L., Pisapia, D., Krasnozhen-Ratush, O., Rosenblum, M., Shroff, S., … Snuderl, M. (2023). Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances, 5(1). https://doi.org/10.1093/noajnl/vdad076

Arrillaga-Romany, I., Gardner, S. L., Odia, Y., Aguilera, D., Allen, J. E., Batchelor, T., Butowski, N., Chen, C., Cloughesy, T., Cluster, A., de Groot, J., Dixit, K. S., Graber, J. J., Haggiagi, A. M., Harrison, R. A., Kheradpour, A., Kilburn, L. B., Kurz, S. C., Lu, G., … Wen, P. Y. (2024). ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal of Clinical Oncology, 42(13), 1542–1552. https://doi.org/10.1200/jco.23.01134

Duffau, H., Berger, M., Brastianos, P. K., Sanai, N., Mandonnet, E., & McKhann, G. M. (2024). Introduction: Contemporary management of low-grade gliomas: from tumor biology to the patient’s quality of life. Neurosurgical Focus, 56(2), E1. https://doi.org/10.3171/2023.11.focus23731

Sprinzen, L., Garcia, F., Mela, A., Lei, L., Upadhyayula, P., Mahajan, A., Humala, N., Manier, L., Caprioli, R., Quiñones-Hinojosa, A., Casaccia, P., & Canoll, P. (2024). EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor. Cells, 13(3), 219. https://doi.org/10.3390/cells13030219

Diaz, M., Chudsky, S., Pentsova, E., & Miller, A. M. (2024). Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors. Translational Oncology, 41, 101881. https://doi.org/10.1016/j.tranon.2024.101881

Picca, A., Di Stefano, A. L., Savatovsky, J., Ducray, F., Chinot, O., Moyal, E. C.-J., Augereau, P., Le Rhun, E., Schmitt, Y., Rousseaux, N., Yepnang, A. M. M., Estellat, C., Charbonneau, F., Letourneur, Q., Branger, D. F., Meyronet, D., Fardeau, C., Mokhtari, K., Bielle, F., … Sanson, M. (2024). TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma. Neuro-Oncology Advances, 6(1). https://doi.org/10.1093/noajnl/vdae068

Chapman, O. S., Luebeck, J., Sridhar, S., Wong, I. T.-L., Dixit, D., Wang, S., Prasad, G., Rajkumar, U., Pagadala, M. S., Larson, J. D., He, B. J., Hung, K. L., Lange, J. T., Dehkordi, S. R., Chandran, S., Adam, M., Morgan, L., Wani, S., Tiwari, A., … Chavez, L. (2023). Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma. Nature Genetics, 55(12), 2189–2199. https://doi.org/10.1038/s41588-023-01551-3

Minns, H., Padilla, O., Wei, H.-J., Gartrell, R. D., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Gallitto, M., Yeh, R., Zhang, Z., Hei, T., Szalontay, L., Pavisic, J., Garty, G., Garvin, J., Canoll, P., Vanpouille-Box, C., Menon, V., … Wu, C.-C. (2023). 53 Inducing immune response with FLASH and conventional radiation in diffuse midline glioma (DMG). Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0053

Prendergast, C. M., Lopci, E., Seban, R.-D., De Jong, D., Ammari, S., Aneja, S., Lévy, A., Sajan, A., Salvatore, M. M., Cappacione, K. M., Schwartz, L. H., Deutsch, E., & Dercle, L. (2023). Integrating [18F]-Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography with Radiation Therapy and Immunomodulation in Precision Therapy for Solid Tumors. Cancers, 15(21), 5179. https://doi.org/10.3390/cancers15215179

Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Larson, J. D., Wechsler-Reya, R. J., Sirianni, R. W., & Elmquist, W. F. (2023). Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors. Journal of Pharmacology and Experimental Therapeutics, 387(3), 315–327. https://doi.org/10.1124/jpet.123.001826

Zarabi, H., Helis, C. A., Russell, G., Huang, J., Liu, W., Soltys, S. G., Mendoza, M., Braunstein, S. E., Salans, M. A., Wang, T. J. C., Gallitto, M., Shi, W., Cappelli, L., Shen, C., Young, M. D., Mignano, J. E., Halasz, L. M., Barbour, A. B., Masters, A. H., & Chan, M. D. (2023). Multi-Institutional Report of Re-Irradiation for Recurrent High-Grade Glioma. International Journal of Radiation Oncology*Biology*Physics, 117(2), S85–S86. https://doi.org/10.1016/j.ijrobp.2023.06.408

Kokossis, D., Wei, H. J., Gallitto, M., Yoh, N., McQuillan, N., Tazhibi, M., Berg, X., Zhang, X., Szalontay, L., Gartrell, R., Jovana, P., Zhang, Z., Molotkov, A., Mintz, A., Konofagou, E. E., & Wu, C. C. (2023). Focused Ultrasound for Blood-Brain Barrier Opening and Delivery of Anti-PD1 in Diffuse Midline Gliomas. International Journal of Radiation Oncology*Biology*Physics, 117(2), e523–e524. https://doi.org/10.1016/j.ijrobp.2023.06.1796

Shi, W., Glas, M., Mrugala, M. M., Iwamoto, F. M., Lukas, R. V., Palmer, J., & Suh, J. (2023). 529P Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022. Annals of Oncology, 34, S402. https://doi.org/10.1016/j.annonc.2023.09.1723

Mrugala, M. M., Shi, W., Iwamoto, F. M., Heidemann, M., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2023). LONG-TERM POST-MARKETING SURVEILLANCE DATA FROM ELDERLY PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY. Neuro-Oncology, 25(Supplement_3), iii2–iii2. https://doi.org/10.1093/neuonc/noad147.007

Sanchini, C., Rosito, M., Comincini, A., De Panfilis, S., Bartolini, F., & Di Angelantonio, S. (2023). Protocol for observing microtubules and microtubule ends in both fixed and live primary microglia cells. STAR Protocols, 4(3), 102499. https://doi.org/10.1016/j.xpro.2023.102499

Rodriguez, J., Martinez, G., Mahase, S., Roytman, M., Haghdel, A., Kim, S., Madera, G., Magge, R., Pan, P., Ramakrishna, R., Schwartz, T. H., Pannullo, S. C., Osborne, J. R., Lin, E., Knisely, J. P. S., Sanelli, P. C., & Ivanidze, J. (2023). Cost-Effectiveness Analysis of68Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma. American Journal of Neuroradiology, 44(7), 783–791. https://doi.org/10.3174/ajnr.a7901

Laternser, S., Petrovic, A., Eze, A., Dettwiler, S., Prutek, F., Contini, P. A., Morinigo, D., Bornhorst, M., Rushing, E. J., McDonough, E., Surrette, C., Ginty, F., Minnis, H., Gartrell, R., Müller, S., Packer, R., & Nazarian, J. (2023). DIPG-25. MAPPING TUMOR MICROENVIRONMENT USING EMERGING TECHNOLOGIES FOR PEDIATRIC BRAIN CANCERS. Neuro-Oncology, 25(Supplement_1), i18–i18. https://doi.org/10.1093/neuonc/noad073.072

Mrugala, M. M., Shi, W., Iwamoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2023). TRLS-07. GLOBAL POST-MARKETING SURVEILLANCE DATA FROM PEDIATRIC AND ADULT PATIENTS WITH CENTRAL NERVOUS SYSTEM MALIGNANCIES TREATED WITH TUMOR TREATING FIELDS (TTFIELDS) THERAPY BETWEEN 2011–2022. Neuro-Oncology, 25(Supplement_1), i80–i80. https://doi.org/10.1093/neuonc/noad073.310

Kokossis, D., Wei, H.-J., Gallitto, M., Yoh, N., McQuillan, N., Tazhibi, M., Berg, X., Zhang, X., Szalontay, L., Gartrell, R. D., Pavisic, J., Zhang, Z., Molotkov, A., Mintz, A., Konofagou, E. E., & Wu, C.-C. (2023). SURG-06. ENHANCED DELIVERY OF ANTI-PD1 FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA USING FOCUSED ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER OPENING. Neuro-Oncology, 25(Supplement_1), i73–i73. https://doi.org/10.1093/neuonc/noad073.282

Fernández, E. C., Wang, J., Zhang, X., Wei, H.-J., Minns, H., Griffin, A., Obradovic, A., Vlahos, L., Martins, T., Becker, P., Crawford, J., Gartrell, R., Szalontay, L., Zacharoulis, S., Zhang, Z., Wechsler-Reya, R., Wu, C.-C., Califano, A., & Pavisic, J. (2023). DIPG-49. A SYSTEMS BIOLOGY APPROACH TO DEFINING AND TARGETING CELL STATE-SPECIFIC MASTER REGULATOR DEPENDENCIES IN DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 25(Supplement_1), i24–i24. https://doi.org/10.1093/neuonc/noad073.096